Literature DB >> 18749356

Internal medicine-important advances in clinical medicine: pulmonary sarcoidosis: indications for treatment.

O P Sharma.   

Abstract

The Scientific Board of the California Medical Association presents the following inventory of items of progress in internal medicine. Each item, in the judgment of a panel of knowledgeable physicians, has recently become reasonably firmly established, both as to scientific fact and important clinical significance. The items are presented in simple epitome and an authoritative reference, both to the item itself and to the subject as a whole, is generally given for those who may be unfamiliar with a particular item. The purpose is to assist busy practitioners, students, research workers or scholars to stay abreast of these items of progress in internal medicine that have recently achieved a substantial degree of authoritative acceptance, whether in their own field of special interest or another.The items of progress listed below were selected by the Advisory Panel to the Section on Internal Medicine of the California Medical Association and the summaries were prepared under its direction.

Entities:  

Year:  1983        PMID: 18749356      PMCID: PMC1010791     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  4 in total

1.  Immunology of sarcoidosis.

Authors:  D G James; W J Williams
Journal:  Am J Med       Date:  1982-01       Impact factor: 4.965

2.  Presentation of sarcoidosis and outcome of pulmonary changes.

Authors:  F K Rømer
Journal:  Dan Med Bull       Date:  1982-01

3.  Gallium-67 in the evaluation of sarcoidosis: correlations with serum angiotensin-converting enzyme and bronchoalveolar lavage.

Authors:  D Beaumont; J Y Herry; M Sapene; P Bourguet; J J Larzul; B de Labarthe
Journal:  Thorax       Date:  1982-01       Impact factor: 9.139

Review 4.  NIH conference. Pulmonary sarcoidosis: a disease characterized and perpetuated by activated lung T-lymphocytes.

Authors: 
Journal:  Ann Intern Med       Date:  1981-01       Impact factor: 25.391

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.